Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia

Graphical abstract

Saved in:
Bibliographic Details
Published inLeukemia research Vol. 56; pp. 36 - 43
Main Authors Quagliano, Anthony, Gopalakrishnapillai, Anilkumar, Barwe, Sonali P
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.05.2017
Subjects
Acute lymphoid leukemia
Animals
Azacitidine
Azacitidine - pharmacology
Azacitidine - therapeutic use
Chemoprotection
Coculture Techniques
DNA Modification Methylases - antagonists & inhibitors
Drug Resistance, Neoplasm - drug effects
Epigenesis, Genetic - drug effects
Epigenetic
Hematology, Oncology and Palliative Medicine
Heterografts
Histone Deacetylase Inhibitors
Humans
Hydroxamic Acids - pharmacology
Hydroxamic Acids - therapeutic use
Indoles - pharmacology
Indoles - therapeutic use
Mice
Osteoblasts
Osteoblasts - pathology
Panobinostat
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - pathology
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology
Tumor Cells, Cultured
Panobinostat
Chemoprotection
Epigenetic
Azacitidine
Acute lymphoid leukemia
Osteoblasts
Online AccessGet full text

Cover

More Information
Summary:Graphical abstract
ISSN:0145-2126
1873-5835
DOI:10.1016/j.leukres.2017.01.030